



## Exchange Traded Product on CECflex Index

### Bullish

Product Category:	Product Type:	SSPA Code:	Offering Type:	Exchange Listing:
Participation Products	Tracker Certificate	1300	Public Offering: CH	Listed on SIX Swiss Exchange

The products (the "Product") documented in this Termsheet may be considered structured products in Switzerland pursuant to article 70 of the Swiss Financial Services Act of 15 June 2018 ("FinSA") and are neither subject to authorization nor supervision by the Swiss Financial Market Supervisory Authority FINMA ("FINMA"). None of the Products constitute a participation in a collective investment scheme within the meaning of the Collective Investment Schemes Act of 23 June 2006 ("CISA") and investors do not benefit from the specific investor protection provided under CISA. Investors bear the credit risk of the Issuer.

Investors should read the section "Risk Factors" of the Base Prospectus and the section "Significant Risks for Investors" of this Termsheet. Investing in this product may put Investor's capital at risk. Investors may lose some or all of their investment.

This Product is collateralised in accordance with the terms and conditions of the TCM Security Agreement for Triparty Collateral Management Secured Structured Products ("TCM Secured Structured Products"). More detailed information regarding the collateralisation can be found in the section "Information about TCM-Collateralisation" below.

Even though translations of documents into other languages might be available, only the English version of the Final Terms and the Base Prospectus of the relevant Issuance and Offering Programme shall form the entire and legally binding documentation for this Product. This Termsheet does not, and is not intended to, constitute, or contain an offer or invitation to sell, and it is not soliciting offers to buy, the Product in any jurisdiction where such offer or sale is not permitted.

This Termsheet constitutes a marketing document within the meaning of article 68 FinSA. It is provided for information and discussion purposes only.

### Product Overview

Any investment decisions must not only be based on the Product Overview but on the entire information contained in the Base Prospectus and the Final Terms. In particular, each investor should consider the risk factors contained in the Base Prospectus and in the Final Terms.

#### Information on the securities

Issuer	Maverix Securities AG, Zurich, Switzerland	Security Codes	
		ISIN:	CH1413566279
		Swiss Security Number:	141356627
		SIX Symbol:	CECFX
SSPA Code	1300 (as defined in the SSPA Swiss Derivative Map)	Underlying Index	CECflex Index
Issue Price	CHF 100.00	Issue Size	Up to 100'000 Product(s) (can be increased at any time)
Settlement Currency	CHF	Settlement Type	Cash Settlement
Initial Fixing Date	30/07/2025	Issue Date	04/08/2025
Final Fixing Date	Open-end	Redemption Date	The 5th Business Day following the Final Fixing Date and subject to Settlement Disruption Event provisions.
Collateralization	Triparty Collateral Management ("TCM") by SIX SIS	Listing	The Products are listed and admitted to trading in Switzerland on SIX Swiss Exchange according to the Exchange Traded Product (ETP) Regulatory Standard. First Exchange Trading Date: 31/07/2025 (anticipated)

### Product Description

The Product replicates the price movements in the underlying Index (adjusted by the Units, the Management Fee and as the case may be the Performance Fee) and is therefore in terms of risk comparable to a direct investment in the underlying Index. On the Redemption Date, the Investor will receive a Cash Settlement in the Settlement Currency, as further described under Redemption.

**Index description:** The underlying Index is a dynamic, actively managed index (the "Index") which is discretionary managed by the Index Sponsor and the Index Administrator and calculated by the Index Calculation Agent. The Index Components (the "Components") of the Index may – subject to the Index Administrator's veto right – be rebalanced by the Index Sponsor on a regular basis. The Index Sponsor determines and is responsible for the composition of the Index and may add, replace or remove Index Components in accordance with a set of predefined rules set out in the Index Rule Book AS49IZ, dated 26/05/2025 (the "Index Rule Book").

**Objective:** The investment objective of the certificate is to systematically select the digital investments in the altcoin area and Bitcoin to achieve high capital growth. Investments are made in large caps. The selection is based on careful research and quantbased evaluations. From this data

analysis Risk on/Risk off signals are generated. The big price setbacks can be minimized in this way. The allocation to cryptocurrencies is between 0% and 100%. Access to the crypto market is generated via exchange - traded ETP (Exchange Traded Products) and ETF (Exchange Traded Funds). The Index Sponsor will pay attention to underlying, which are taking the aspect of the so-called "cold storage" into account.

**Universe:** The Index universe consists of eligible Index Components which may include Cash Instruments, ETFs, Listed Structured Products or ETPs and FX Spot as determined by the Index Sponsor and subject to the restrictions defined in the Index Rule Book.

**Distributions:** Net distributions with respect to Components (after deduction of any expenses and taxes) will lead to an adjustment of the Index (as specified in the Index Rule Book).

**The Index represents a hypothetical portfolio. There is no obligation of the Index Calculation Agent, the Issuer or any other party to purchase and/or hold any Components and there is no actual portfolio of assets to which any person is entitled or in which any person has an ownership interest. The Index consists of Components, the performance of which will be used as a reference point for the purposes of calculating the value of the Index. The Issuer shall be free to choose how to invest or further proceed with any proceeds of the issuance of any of the Products. References to any rebalancing of the Index or addition, adjustment, substitution, replacement or removal of Components should not be construed as imposing an obligation on the Issuer, the Index Calculation Agent or any person to acquire or dispose of any securities, investments, assets or other property but are references to the change in, and relate solely to the calculation of, the value of the Index, which is relevant for the determination of any amount payable in respect of the Products.**

Upon request, the Index Rule Book and the latest composition of the Index are available free of charge from the Index Calculation Agent (Maverix Securities AG, Tessinerplatz 7, 8002 Zurich, Switzerland) or can be downloaded on [www.cuglos.com](http://www.cuglos.com).

## Underlying Index Information

Index	Index Sponsor	Index Calculation Agent	Index Administrator	Units <sub>0</sub>	Index Currency	Initial Fixing Level (Index Value <sub>0</sub> )
CECFlex Index	Maverix Securities AG	Maverix Securities AG	Maverix Securities AG	1.0000	CHF	CHF 100.00

## Product Details

Security Codes	
ISIN:	CH1413566279
Swiss Security Number:	141356627
SIX Symbol:	CECFX
Issue Price	CHF 100.00
Issue Size	Up to 100'000 Product(s) (can be increased at any time)
Settlement Currency	CHF

## Dates

Subscription Start Date	14/07/2025
Subscription End Date	30/07/2025 (please note that the Subscription Period might be closed earlier)
Initial Fixing Date	30/07/2025 (or the day when the Subscription Period ends)
Issue Date	04/08/2025
First Exchange Trading Date	04/08/2025 (anticipated)
Last Trading Date	Open-end or in case of an exercise of the Issuer's Termination Right two Scheduled Trading Days prior to the Final Fixing Date.
Final Fixing Date	Open-end or in case of an exercise of the Issuer's Termination Right, as specified in the Issuer's Termination Announcement or in case of an exercise of the Investor Redemption, the day for which the Product Administrator receives the duly signed Redemption Notice (subject to Market Disruption Event provisions).
Redemption Date	The 5th Business Day following the Final Fixing Date and subject to Settlement Disruption Event provisions.
Observation Dates	Daily, from (and including) Issue Date; if a specific Observation Date is not a Scheduled Trading Day then the following Scheduled Trading Day will be deemed to be an Observation Date.
Determination Dates	Quarterly, from (and including) 15/09/2025; if a specific Determination Date is not a Scheduled Trading Day then the following Scheduled Trading Day will be deemed to be a Determination Date.

## Fees

Distribution Fee (DF)	No Distribution Fee is charged.
Management Fee (MF)	Up to 1.70% p.a.; the Management Fee reduces the redemption amount subject to the holding period and has a negative effect on the secondary market prices. The Management Fee is calculated daily and is payable quarterly within 10 Business Days of its determination on the Determination Date(s) by the Issuer to the following parties:

	Index Advisor	1.25% p.a. out of the up to 1.70% p.a.
	Index Sponsor	Up to 0.45% p.a. out of the up to 1.70% p.a.
Performance Fee (PF)	15.00% on each Observation Date taking into account the High Watermark; the Performance Fee reduces the redemption amount and has a negative effect on the secondary market prices. The Performance Fee is calculated daily and is payable quarterly within 10 Business Days of its determination on the Determination Date(s) by the Issuer.	
Rebalancing Fee	<p>The Index Administrator charges a Rebalancing Fee for each adjustment made to an Index Component within the Index. The fee is calculated based on the asset category of the traded financial instrument. It may be expressed as a percentage of the notional volume of the respective transaction in the Index Component or as a specific amount, as further described in the Index Rule Book.</p> <p>Market charges (e.g., stamp duty and exchange fee) and execution costs incurred by the Issuer in relation to its hedging activities, as determined by the Index Administrator in its sole discretion, will be charged in addition to the Rebalancing Fee.</p> <p>Changes in the Units<sub>t</sub> in the Index are exempt from the Rebalancing Fee.</p>	
Other Fees	Additional fees may be charged for individual Index Components (e.g., for required infrastructure or required audits).	

## Redemption

The Investor is entitled to receive from the Issuer, subject to an early redemption, on the Redemption Date per Product a Cash Settlement in the Settlement Currency corresponding to the value of the underlying Index on the Final Fixing Date adjusted by the Units<sub>t</sub>, the Management Fee and as the case may be the Performance Fee. This amount equals Value<sub>t</sub> on the Final Fixing Date, where Value<sub>t</sub> is calculated according to the following formula and reasonably determined by the Product Calculation Agent:

$$\text{Value}_t = \text{Units}_{t-1} \times \text{Index Value}_t - \text{AMF}_t - \text{PF}_t$$

On any Observation Date, the Value<sub>t</sub> is calculated based on the AMF<sub>t</sub> and PF<sub>t</sub> before the adjustment of Units<sub>t</sub> is made.

Initial Fixing Level (Index Value <sub>0</sub> )	Official close of the Underlying Index on the Initial Fixing Date, as determined by the Index Calculation Agent.
Final Fixing Level	Official close of the Underlying Index on the Final Fixing Date as published by the Index Calculation Agent and as determined by the Product Calculation Agent in its reasonable discretion (billiges Ermessen).
Units <sub>t</sub>	<p>The notional units of the Index per Product on Scheduled Trading Day<sub>t</sub>.</p> <p>Provided Scheduled Trading Day<sub>t</sub> is not an Observation Date:</p> <p><b>Units<sub>t</sub> = Units<sub>t-1</sub></b></p> <p>If Scheduled Trading Day<sub>t</sub> is an Observation Date:</p> <p><b>Units<sub>t</sub> = Value<sub>t</sub> / Index Value<sub>t</sub></b></p> <p>Where Index Value<sub>t</sub> is the Value of the Index on Scheduled Trading Day<sub>t</sub>, adjusted by any costs incurred by the Issuer or a hedging party thereof for unwinding risk reducing hedging transactions relating to the Issuer's obligations under the Product, as reasonably determined by the Index Calculation Agent.</p> <p>Following the adjustment of Units<sub>t</sub> by the AMF<sub>t</sub>, AMF<sub>t</sub> is reset to zero.</p> <p>Following the adjustment of Units<sub>t</sub> by the PF<sub>t</sub>, HWM<sub>t</sub> is reset according to the rule below.</p>
Index Value <sub>t</sub>	The last available value of the Index on Scheduled Trading Day <sub>t</sub> as published and as reasonably determined by the Index Calculation Agent.
AMF <sub>t</sub>	<p>The Accrued Management Fee on Scheduled Trading Day<sub>t</sub> is determined by the Index Calculation Agent as follows:</p> <p><b>AMF<sub>t</sub> = AMF<sub>t-1</sub> + Value<sub>t-1</sub> × MF × Day Count<sub>t</sub> and AMF<sub>0</sub> = 0.00</b></p>
PF <sub>t</sub>	<p>The Performance Fee on Scheduled Trading Day<sub>t</sub> is determined by the Index Calculation Agent as follows:</p> <p><b>PF<sub>t</sub> = PF × MAX(0; Units<sub>t-1</sub> × Index Value<sub>t</sub> - AMF<sub>t</sub> - HWM<sub>t-1</sub>)</b></p>
Day Count <sub>t</sub>	Actual number of calendar days between Scheduled Trading Day <sub>t-1</sub> to the current Scheduled Trading Day <sub>t</sub> divided by 360.
High Watermark <sub>t</sub> (HWM)	On each Observation Date, the HWM <sub>t</sub> shall be the greater of HWM <sub>t-1</sub> and the Value <sub>t</sub> . On any other Scheduled Trading Day <sub>t</sub> HWM <sub>t</sub> remains unchanged. The High Watermark HWM <sub>0</sub> on the Initial Fixing Date equals the Value <sub>0</sub> .
Scheduled Trading Day <sub>t</sub>	Means any calendar day on which the Index Calculation Agent is scheduled to publish a value for the Underlying. The Initial Fixing Date corresponds to Scheduled Trading Day <sub>0</sub> and for any subsequent Scheduled Trading Day variable t is incremented by one (1).
Issuer Termination Right	The Issuer has the unconditional right to call the outstanding and issued size for early redemption (the "Termination Right") at any time with a 10 Business Days (prior to the respective Final Fixing Date) notice by announcement (the "Termination Announcement") published on www.cuglos.com. The Termination Announcement will specify the adjusted Final Fixing Date and the adjusted Redemption Date. Following the announcement, the Product will be redeemed on the adjusted Redemption Date for an amount in the Settlement Currency that equals the Value <sub>t</sub> on the communicated adjusted Final Fixing Date, as determined by the Product Calculation Agent.

Investor Redemption Right	Each Investor has an annual right, first time on the anniversary of the Issue Date (such day being the “ <b>Announcement Date</b> ”; following Business Day Convention will apply) to call, the portion of the outstanding size in which they are invested to, for redemption (taking into account any Minimum Redemption Number, if such is applicable as stated under “General Information” herein), by delivering a duly completed and signed Redemption Notice to the Issue and Paying Agent (notice to be received by the Issue and Paying Agent no later than 07:00 am CET/CEST, 10 Business Days preceding the respective Announcement Date). Following such announcement, the called portion of the outstanding size will be redeemed 5 Business Days after the Announcement Date, for an amount in the Settlement Currency that equals the Value, on the Announcement Date, as determined by the Product Calculation Agent. Payments are dependent on the index universe and may be delayed due to liquidity or index component characteristics, such as but not limited to exit conditions or times.
Extraordinary Termination	The early termination rights pursuant to the General Conditions and the Underlying Specific Conditions apply. See in particular the following provisions: General Condition 19 (Termination and Cancellation due to Illegality, Illiquidity, Impossibility, Increased Cost of Hedging, Hedging Disruption, Increased Cost of Collateralisation (ETPs) or Changed Secured Financing Ability), General Condition 29 (Market Disruption), General Condition 32 (Postponement of Adjustments due to Cash Settlement Disruption, Payment Disruption due to the Occurrence of a Foreign Exchange Disruption Event) and Underlying Specific Conditions 3.3.

## Description of the Issuer and Principal Parties

Issuer	Maverix Securities AG, Zurich, Switzerland Supervised by: Swiss Financial Market Supervisory Authority (FINMA)
Issue and Paying Agent	Maverix Securities AG, Zurich, Switzerland
Index Administrator	Maverix Securities AG, Zurich, Switzerland
Index Advisor	inpearl capital AG, Hünenberg, Switzerland
Index Calculation Agent	Maverix Securities AG, Zurich, Switzerland
Index Sponsor	Maverix Securities AG, Zurich, Switzerland
Authorized Participant	Maverix Securities AG, Zurich, Switzerland
Product Administrator	Maverix Securities AG, Zurich, Switzerland
Product Calculation Agent	Maverix Securities AG, Zurich, Switzerland
Collateral Agent	SIX Repo AG, Zurich, Switzerland
Collateral Custodian	SIX SIS AG, Olten, Switzerland
Collateral Provider	Maverix Securities AG, Zurich, Switzerland

## General Information

Listing/Exchange	The Products are listed on SIX Swiss Exchange according to the Exchange Traded Product (ETP) Regulatory Standard. First Exchange Trading Date: 04/08/2025 (anticipated)
Secondary Market	The Issuer intends to provide a daily secondary market under normal market conditions with a maximum bid-offer spread of 1.00%. Daily price indications will be available from 09:00 - 17:30 CET on Bloomberg [ISIN] Corp and/or on www.cuglos.com.
Quotation Type	Secondary market prices are quoted in the Settlement Currency per product.
Settlement Type	Settlement in cash only (“Cash Settlement”). There is no physical delivery of Underlying Component(s) to Investors.
Minimum Investment	1 Product(s)
Minimum Trading Lot	1 Product(s)
Minimum Redemption Number	1 Product(s)
Clearing	SIX SIS AG, Euroclear
Depository	SIX SIS AG
Public Offering	CH
Form	Uncertificated Security / Book-entry
Governing Law/Jurisdiction	Swiss / Zurich

## Swiss Taxation

Swiss Federal Stamp Duty	Transactions in the Product are not subject to Swiss Federal Stamp Duty.
Swiss Federal Income Tax (for private Investors with tax domicile in	For Swiss income tax purposes, the product is treated analogously to a share/unit in an investment fund. All reinvested dividend and interest income from the Underlying are subject to income tax. The taxable

Switzerland)	income (if any) generated by the Product will be reported annually to the Swiss Federal Tax Administration. For private investors with tax domicile in Switzerland who hold the Product as private assets, the reported income (if any) is subject to direct federal tax. Any dividend payments are subject to direct federal tax on the respective payment date. If no tax reporting is available, the taxable income is determined based on a fair market return, taking into account the asset classes of the Underlying. The tax treatment for cantonal and municipal income taxes may differ from the tax treatment for direct federal tax. In general, however, the income tax treatments are the same.
Swiss Withholding Tax	The Product is not subject to the Swiss Withholding Tax.

The Swiss tax information provided herein is a non-binding summary and only provides a general overview of the potential Swiss tax consequences linked to this Product at the time of issue. Swiss tax laws and administrative practice may change, possibly with retroactive effect.

Investors and prospective Investors are advised to consult with their Swiss or foreign tax advisers with respect to the Swiss or foreign tax consequences of the purchase, ownership, disposition, lapse or exercise or redemption of a Product in light of their particular circumstances. The Issuer and the Paying Agent hereby expressly exclude any liability in respect of any possible Swiss or foreign tax consequences.

#### Information with regards to FATCA (Foreign Account Tax Compliance Act)

Any payment under this Product may be subject to withholding tax (such as, inter alia, withholding related to FATCA or 871(m) of the US Tax Code). Any payments due under this Product are net of such tax. If an amount in respect of Section 871(m) of the U.S. Tax Code were to be deducted or withheld from interest, principal or other payments on the Products, none of the Issuer, any Paying Agent or any other person would be required to pay additional amounts as a result of the deduction or withholding of such tax, i.e. the Investor would receive a significant lower amount than he would have received without such deduction or withholding.

#### Prospects for Profit and Loss

This product falls within the category "Participation Products". The profit the Investor could realize with this Product at redemption is unlimited (except for bearish products and products with the special feature "capped participation"). The redemption amount is directly linked to the performance of the Index Component(s), taking into account any participation rates or other features.

On the downside the Investor is exposed to the development of the Index Component(s). This might lead to a partial or even a total loss of the investment.

Please refer to the sections "Product Description" and "Redemption" for more detailed information on the characteristics of this Product.

#### Information about Triparty Collateral Management by SIX

Triparty Collateral Management Secured Products ("TCM Products") are products with a reduced issuer risk. This protection is provided by means of a collateral pledge. Investors thus profit from increased protection on the invested capital.

The Collateral Provider has entered into the Security Agreement on 09 May 2023 ("Security Agreement") and TCM Products are collateralised in accordance with the terms of the Security Agreement. The Collateral Provider will provide collateral to secure the value of TCM Products, whereby such collateral can consist among others of the securities that are the direct or indirect underlying's of the TCM Product.

The legal position of the Investors and of all involved parties in relation to the collateralisation of the TCM Product is determined by the provisions of the Security Agreement. The Issuer shall, upon request, provide the Security Agreement to the Investors free of charge. A copy of the Security Agreement may be obtained from the Product Administrator at Tessinerplatz 7, 8002 Zurich, Switzerland, or via telephone (+41 43 311 27 40\*) or via e-mail (products@mavx.com). Please note that all calls made to numbers marked with an asterisk (\*) are recorded. By calling such number, your consent to the recording is deemed given.

More detailed information regarding TCM-Collateralisation can also be found in the Programme.

The costs with respect to the collateralisation of TCM Products as well as the borrowing costs of the products collateral may be considered for the pricing of TCM Products and may therefore be borne by the Investors, as the case may be.

The payment to the Investors in case of a so-called Realization Event may be delayed for factual or legal reasons.

#### Significant Risks for Investors

Prospective Investors should ensure that they fully understand the nature of this Product and the extent of their exposure to risks and they should consider the suitability of this Product as an investment in the light of their own circumstances and financial condition. Products involve a high degree of risk, including the potential risk of expiring worthless. Potential Investors should be prepared in certain circumstances to sustain a total loss of the capital invested to purchase this Product as well as the transaction costs. Prospective Investors shall consider the following exemplary selection of important risk factors and read the section "Risk Factors" of the Base Prospectus for details on all other risk factors to be considered.

Investors should make sure that their advisors have verified that this Product is suitable for their portfolio taking into account the investor's financial situation, investment experience and investment objectives.

The Conditions of the Product may be subject to adjustments during the lifetime of the Product as set out in the Base Prospectus.

**Product Specific Risks:** Investors may lose some or all of their investment as well as the transaction costs as they are fully exposed to the performance of the Underlying Index. The Product does not confer any claim to receive rights and/or payments of the Underlying Index, such as dividend payments, unless explicitly stated in the documentation governing the Product. Please refer to the Product Documentation as regards the further Product specific risk factors to be taken into account.

**Issuer Risk:** Investors are exposed to the credit risk of the Issuer to the extent that the proceeds from the liquidation of collateral upon occurrence of an Event of Default (less the costs of liquidation and payout) are not sufficient to cover the Investors' claims. If the Issuer is not able to make a payment or becomes insolvent, investors could lose some or all of their investment.

**Market Risk:** Market risk may have a negative impact on the value of and the return on an investment in the Product. Market risk is the risk associated with the effect of changes in market factors such as interest and foreign exchange rates, equity and commodity prices, credit spreads or implied volatilities, on the value of assets and liabilities held for both the short and long term. Market risk may also lead to an early redemption of the Product (e.g. in the event of a hedging disruption).

**Liquidity Risk:** The Issuer or a third party appointed by the Issuer, intends to act as market maker in relation to the Product and it will use commercially reasonable efforts to provide indicative bid and offer prices for the Product on a regular basis under normal market conditions. However, such market maker does not have an obligation to provide prices for the Product. Liquidity of the Product in the secondary market may be limited and an active trading market for the Product may not develop. Accordingly, investors may not be able to sell their Product.

**Currency Risk:** If the investor's reference currency is different from the currency, in which the Product is denominated, the investor bears the currency risk between the two currencies. The fluctuations in exchange rates could have an adverse effect on the value of or return on an investment in the Product, even if the redemption amount would otherwise provide for a positive return. If the Index Component(s) are calculated in a currency different from the Settlement Currency, the conversion into the Settlement Currency will be carried out at the relevant exchange rate.

**Early Termination and Reinvestment Risk:** The Product may be redeemed prior to its maturity (be it by declaration of the Issuer or as a result of certain events specified in the terms of the Product) and Investors must consider that in case of such an early redemption, investors will not receive any further coupon payments after the occurrence of the early redemption and the early redemption amount may be significantly below the issue / purchase price paid and the redemption amount payable at maturity. Investors may not be able to reinvest the early redemption amount in a financial instrument with the same profit potential and additional transaction costs may be incurred as a consequence of a reinvestment of the early redemption amount.

**Illiquidity of Underlying:** One or, if applicable, more of the Index Component(s) might be or become illiquid over the lifetime of the Product. Illiquidity of an Index Component might lead to larger bid/offer spreads of the Product and/or to an extended time period for buying and/or selling the Index Component respective to acquire, unwind or dispose of the hedging transaction(s) or asset(s) or to realise, recover or remit the proceeds of such hedging transaction(s) or asset(s) which might implicate a postponed redemption or delivery and/or a modified redemption amount, as reasonably determined by the Index Calculation Agent.

**Equalization issue caused by intraday Performance Fee:** The high watermark as the basis of the performance fee is observed daily. If the product has an unrealized performance fee at the time of a new investment, the new client will pay a lower price compared to a product that has no performance fee. However, in the event of a subsequent negative performance, the portfolio might lose more than the new client paid (asymmetric price behaviour). In such an event, the unrealized performance fee is not realized, and any negative impact is transferred to the Underlying Index as determined by the Index Administrator. In any case, no performance fee is charged on the new investments until the next observation.

**Conflict of Interests:** The Issuer and the Principal Parties and/or any third party appointed by them, as the case may be, may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market as well as be active on both sides of the market at the same time in any securities, currencies, financial instruments or other assets underlying the Products to which this document relates. The Issuer's and Principal Parties' and/or the appointed third party's trading and/or hedging activities related to this Product may have an impact on the price of the Component(s).

**Remunerations to Third Parties:** Depending on the circumstances the Issuer and/or the Principal Parties may sell this Product to financial institutions or intermediaries at a discount to the Issue Price or reimburse a certain amount to such financial institutions or intermediaries (reference is made to section "General Information" or "Fees" herein).

In addition, for certain services rendered by distribution partners and to increase quality and services relating to the Products, the Issuer and/or the Principal Parties may from time to time pay trailer fees to such third parties.

Further information is available on request.

**Tax Impact:** There may be a tax impact on investing in the Product. The Issuer and the Principal Parties do not provide any tax opinion. Any Investor should consult with its own tax advisor prior to investing in the Product. In addition, Investors should be aware that taxation with respect to the Index Component(s) and therefore, this Product may (adversely) change over the lifetime of the Product. In accordance with the General Terms and Conditions the Issuer and the Principal Parties have the right, but not the duty, to withhold or deduct any such taxes, duties, fees and/or charges.

**Foreign Exchange Risk:** The Investor in the Product is exposed to foreign exchange rate risk if the currency of the Index Component(s) and Settlement Currency are not identical.

**Role of the Index Administrator and Index Calculation Agent:** Maverix Securities AG acts as Index Administrator and Index Calculation Agent in respect of the Underlying Index. In these capacities, it may amend or discontinue the Index Rule Book, is under no obligation to take into account the interests of an Investor of the Products. Any such determinations made by Maverix Securities AG in relation to the Underlying Index may have a negative impact on the value of and return on the Products.

## Selling Restrictions

No action has been or will be taken to permit a public offering of the Products or possession or distribution of any offering material in relation to the Products in any jurisdiction, where such action for that purpose is required. Consequently, any offer, sale or delivery of the Products, or distribution or publication of any offering material relating to the Products, may only be made in or from any jurisdiction in compliance with applicable laws and regulations not imposing any obligations on the Issuing Parties or the Product Administrator. Possible limitations resulting from legal restrictions regarding cross-border communication and cross-border business concerning the Products and related information remain reserved.

Most important jurisdictions where the Products may not be publicly distributed are Singapore, Hong Kong, Panama, Liechtenstein, Dubai, United Kingdom, European Economic Area.

The Products neither have been nor will be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and the Products may neither be offered nor sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

Detailed information on Selling Restrictions is published in the Base Prospectus which is available on [www.cuglos.com](http://www.cuglos.com) and can be ordered free of charge from the Product Administrator.

## Legal Notice / Disclaimer

**Product Documentation:** It is intended that the Products will be issued under a base prospectus ("Base Prospectus") as per article 45 FinSA approved by SIX Exchange Regulation AG ("SIX Exchange Regulation") in its capacity as Swiss Prospectus Office. Only the Final Terms, which will be available no later than on the Issue Date, together with the Base Prospectus dated 04/07/2025 containing all further relevant terms and conditions, shall form the entire and legally binding documentation for this Product ("Product Documentation"). The Final Terms should always be read together with the Base Prospectus. Definitions used in the Final Terms, but not defined herein, shall have the meaning given to them in the Base Prospectus. Even though a translation into other languages might be available, only the English version of the Final Terms together with the Base Prospectus are legally binding.

Products may be offered, sold or advertised, directly or indirectly, in Switzerland to retail clients (Privatkundinnen und -kunden) in the meaning of the FinSA ("Retail Clients") in accordance with the FinSA.

A Swiss key information document / key information document in accordance with Regulation (EU) No 1286/2014 (PRIIPs Regulation) has been prepared in relation to the Products and may be obtained, free of charge, upon request from the Product Administrator (see the contact details below).

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Product Administrator at Tessinerplatz 7, 8002 Zurich, via telephone +41 43 311 27 40\* or via e-mail ([products@mavx.com](mailto:products@mavx.com)). Please note that all calls made to numbers marked with an asterisk (\*) are recorded. By calling such number, your consent to the recording is deemed given.

**No Offer:** This Termsheet is primarily provided for information purposes and does not constitute a recommendation, an offer or a solicitation of an offer to buy financial products.

**No Representation:** The Issuer, the Product Administrator and any third party appointed by them make no representation or warranty relating to any information herein which is derived from independent sources.